Últimas noticias sobre Pfizer (NYSE:PFE) Bolsa

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFIZER ORD

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

The US stock market experienced a downward trend on Thursday, with both the Nasdaq Composite and the S&amp;P 500 indices falling by nearly 0.6% respectively. The Dow also traded down by 0.5% to 43,750.86. This came amidst news of a 0.2% rise in U.S. producer prices for October.
Federal Reserve Chair Jerome Powell highlighted the resilience of the U.S. economy, suggesting there's <a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates">no rush to lower rates</a>, though future decisions will be data-driven. The equity markets had a negative reaction to Powell&#8217;s comments.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
Palantir&#8217;s shares closed down 2.50% at $59.18, with an intraday high of $61.17 and a low of $58.53. The stock&#8217;s 52-week high and low stand at $63.39 and $15.66 respectively. The company announced it will transfer its <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41994158/palantir-stock-is-rising-after-the-bell-whats-going-on">stock listing to the Nasdaq</a>, expected to commence on Nov. 26.
Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
Moderna&#8217;s stock fell by 5.62% to close at $39.77. The shares traded between $42.06 and $38.76 through the day, with a 52-week range of $170.47 and $38.76. The <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">appointment</a> of vaccine skeptic Robert F. Kennedy Jr. as Health Secretary by President-elect Donald Trump sent vaccine stocks lower.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41963342/elizabeth-warrens-sarcastic-take-on-doges-split-leadership-gets-slammed-by-elon-musk-unlike-you-neither-of-us-are-being-paid?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elizabeth Warren&#8217;s Sarcastic Take On DOGE&#8217;s Split Leadership Gets Slammed By Elon Musk: &#8216;Unlike You, Neit</a>
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)
Pfizer&#8217;s shares closed down 2.62% at $26.02, with an intraday high of $26.85 and a low of $25.84. The 52-week high and low for the stock are $31.54 and $25.2 respectively. The stock was affected by the same news as Moderna.
Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)
Alibaba&#8217;s shares fell by 1.54% to close at $90.58. The stock hit an intraday high of $91.56 and a low of $90.01. The 52-week range for the stock is $117.82 and $66.63. The company is set to unveil its second-quarter earnings on Friday, amidst a <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41991453/alibaba-q2-earnings-could-hint-at-a-turnaround-but-bearish-signals-loom-over-charts">challenging macroeconomic environment</a> and increased competition.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s shares fell by 5.77% to close at $311.18. The shares traded between $329.98 and $310.37 through the day, with a 52-week range of $358.64 and $138.8. Investment veteran Gary Black <a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">warned</a> that Tesla&#8217;s earnings could be hit hardest if the $7,500 federal electric vehicle tax credit is eliminated.
Image via Shutterstock
Prepare for the day&#8217;s trading <a href=""Premarket">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41927985/bitcoin-ethereum-consolidate-dogecoin-surges-as-election-rally-takes-a-breather-analyst-says-pullback-typical-for-healthy-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Consolidate, Dogecoin Surges As Election Rally Takes A Breather: Analyst Says Pullback &#8216;Typical&#8217; For Healthy Market</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

News

Markets

BABA

MRNA

PLTR

TSLA

Palantir, Moderna, Pfizer, Alibaba, Tesla: Why These 5 Stocks Are On Investors' Radars Today

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Government

Regulations

Health Care

Politics

Movers

NVAX

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

Trading Ideas

AVGO

LRCX

SBUX

TRGP

Viking Fund Management 13F Shows Increased Stake In Broadcom From 16,510 To 162,100 Shares; Xcel Energy From 122,400 To 162,400 Shares; Chevron From 58,000 To 70,000 Shares; Starbucks From 87,000 To 105,000 Shares; Lam Research From 4,000 To 10,000 Shares; Pfizer From 286,000 To 344,000 Shares; Targa Resources From 81,000 To 60,000 Shares; Kinder Morgan From 50,000 To 75,000 Shares

<a href="https://x.com/DonaldJTrumpJr/status/1857168002837352564" title="https://x.com/DonaldJTrumpJr/status/1857168002837352564">https://x.com/DonaldJTrumpJr/status/1857168002837352564</a>

Biotech

General

BNTX

Donald Trump Jr. Posts On X "Robert F Kennedy Jr will be The Secretary of Health and Human Services! Promises Made Promises Kept"

WIIM

Shares of vaccine stocks are trading lower following a report suggesting president-elect Trump is expected to nominate Robert F. Kennedy Jr. to lead the HHS.

<a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617</a>
&nbsp;
President-elect Donald Trump is expected to nominate former presidential candidate and anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Services, according to a person with direct knowledge of the selection.
The expected pick, which will roil many public health experts, comes after Trump promised to let Kennedy <a href="https://www.politico.com/video/2024/10/28/trump-says-he-would-let-rfk-jr-go-wild-on-medicines-1466853">"go wild" with health</a> and food policy in his administration after Kennedy dropped his own presidential bid to endorse the now-president-elect. It's also a sign of the opening Trump sees after he scored a decisive electoral victory and Republicans won a comfortable majority in the Senate.
Trump could still select someone else for the post. The Trump transition couldn't immediately be reached for comment.
"He's going to help make America healthy again. … He wants to do some things, and we're going to let him get to it," Trump said in his victory speech. "Go have a good time, Bobby."

'Trump Expected To Select Robert F. Kennedy Jr. To Lead HHS; The Choice Will Roil Many Public Health Experts After His Years Of Touting Debunked Claims That Vaccines Cause Autism' - Politico

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) reported its third quarter revenue grew&nbsp;14% on an operational basis&nbsp;due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. But, even with Covid-19 still lingering in the air, Moderna has also focused on harnessing the power of mRNA to make biotech history by revolutionizing cancer treatment. However, there is also a significant advancement in early screening and even possible prevention when it comes to the cancer front. For example, their much smaller peer,&nbsp;Mainz Biomed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) just announced a new collaboration agreement aimed at developing and potentially commercializing its next generation colorectal cancer screening product.
Mainz Biomed&rsquo;s next generation CRC screening product is coming to redefine standards.
Mainz Biomed is a molecular genetics diagnostic company specialized in the early detection of cancer. This week, it announced it entered into a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmo#NYSE">TMO</a>), through its subsidiary Life Technologies Corporation, a leading provider of life sciences solutions and services.
With the power of Thermo Fisher&rsquo;s powerful technologies, instrumentation and information translation systems, Mainz Biomed will be empowered to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are raising the bar when it comes to early cancer detection. With U.S. and European clinical trials of its flagship non-invasive test, Mainz Biomed promises to redefine standards in cancer screening. With ColoAlert, Mainz Biomed not only offers the early detection of colorectal cancer but also detects advanced adenomas which are a known cancer precursor, therefore, opening the doors its peers didn&rsquo;t dare to tackle, the ones of cancer prevention.&nbsp;
Pfizer topped estimates and hiked its full year guidance.&nbsp;
Cancer drugs brought in $854 million to Pfizer&rsquo;s revenue table, including $409 million from a targeted treatment for bladder cancer called Padcev and $268 million from lymphoma-targeting Adectris. Good results provided some much-needed good news for Pfizer CEO Albert Bourla, who is facing new pressure from activist investor Starboard Value.
For the third quarter, Pfizer reported overall revenue of &nbsp;$17.7 billion.
Moderna continues to focus on developing cancer treatment along with lowering costs.
Back in September, Moderna revealed its plan to cut its research and development budget by $1.1 billion over the next three years while it aims to get FDA approval for 10 products like cancer treatments and vaccines. During the latest earnings call, Moderna CEO St&eacute;phane Bancel was pleased with the cost efficiency achieved during the quarter, with the progress being even better than planned. For the third quarter, Moderna reported revenue of&nbsp;$1.86 billion, smashing LSEG&rsquo;s consensus estimate of $1.25 billion. While Pfizer already counts on oncology for boosting sales, Moderna&rsquo;s sales are still made by the Covid shot, along with RSV one that brought&nbsp;&nbsp;$10 million in U.S. sales after gaining approval in May. However, with 45 products in development powered by its messenger RNA platform, Moderna expects to bring 10 of them to the market over the next three years.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Penny Stocks

MYNZ

The Oncology Bet Is Already Paying Off For Pfizer

Pfizer Exec Says The Impact Of IRA On Co Is "Something We Can Likely Manage"

A teenager in British Columbia is in critical condition after contracting what is believed to be Canada's first human case of <a href="https://www.benzinga.com/general/health-care">the bird flu</a>.
The teen, previously healthy with no underlying conditions, has rapidly deteriorated due to avian influenza, health officials announced this week.
Provincial health officer Bonnie Henry <a href="https://www.cpac.ca/headline-politics/episode/bc-update-on-avian-flu-detection--november-12-2024?id=517eff56-84a5-4ef7-a146-347a1ab8ce8f">revealed</a> in a Tuesday video that the teenager was previously healthy with &#8220;no underlying conditions.&#8221;
See Also: <a href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare">Trump&#8217;s Second Term Could Reshape Healthcare, With Major Impacts on Affordable Care Act And Medicare</a>
The virus can progress and &#8220;cause quite severe illness&#8221; and rapid deterioration, Henry said, adding that the the virus doesn&#8217;t spread easily between people.
In Canada, British Columbia alone has confirmed that there have been flu outbreaks at 26 premises. Numerous wild birds tested positive.
Canada has reported no cases in dairy cattle or evidence of the virus in milk samples.
The investigation is ongoing. Officials are urging the public to stay vigilant as cases rise among both domestic and wild animals.
The British Columbia teenager first showed symptoms on Nov. 2, including conjunctivitis, fever and coughing. The patient was hospitalized on Nov. 8 and is in intensive care with acute respiratory distress syndrome.
<h3 class="wp-block-heading">&#8216;I Don't Want To Have Us Go Backward&#8217;</h3>
In the U.S., the spread of bird flu is growing. The U.S. Centers for Disease Control and Prevention has <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">tallied</a> 46 confirmed human cases this year. Almost all of them are in dairy workers.
About 450 dairy farms across 15 U.S. states since March have reported cases.
The virus grabbed headlines last month when the U.S. Department of Agriculture said a pig at an Oregon farm contracted the bird flu.
&#8220;That is concerning to us,&#8221; said Canadian health official Henry. Pigs can become infected with bird and human viruses, which can change their genetic material and create a new virus that might transmit more easily between humans, she said. 
Such instances can very well lead to the &#8220;starting of the next pandemic,&#8221; she added.
The situation is particularly alarming to the CDC considering the way President-elect Donald Trump handled the COVID-19 outbreak during his first term. Trump has promised to allow Robert F. Kennedy Jr. — a <a href="https://www.benzinga.com/news/24/11/41794198/trump-has-asked-me-to-do-3-things-says-robert-kennedy-jr">proud vaccine skeptic</a> — to <a href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics">&#8220;go wild on health</a>.&#8221;
CDC Director Mandy Cohen seemed to be apprehensive about whether the U.S. is going &#8220;backward&#8221; in comments made Wednesday at the Milken Institute Future of Health Summit in Washington, <a href="https://www.bloomberg.com/news/articles/2024-11-13/cdc-chief-warns-about-rfk-jr-s-skeptical-views-on-vaccines?sref=TBDibEcD">per</a> Bloomberg.
"We have a very short memory of what it is like to hold a child who has been paralyzed with polio, or to comfort a mom who lost their kid from measles," Cohen said. "I don't want to have to see us go backward in order to remind ourselves that vaccines work.&#8221;
<h3 class="wp-block-heading">Which Companies Are Preparing Bird Flu Vaccines?</h3>
Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) are continuing efforts to develop an mRNA bird flu vaccine — the same technology used in the companies&#8217; respective COVID-19 vaccines.
Federal health officials announced last month that $72 million in funding will go toward vaccine development, according <a href="https://abcnews.go.com/Health/us-72m-vaccine-manufacturers-advance-bird-flu-shot/story?id=114502971">to</a> ABC News.
Price Action: Pfizer is trading at $26.36 per share, up 0.65% at last check Wednesday. Moderna is trading at $42.46 per share, down 2.32%.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" target="_blank" rel="noreferrer noopener">Trump's Potential ‘Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: ‘Shoot First Reaction'</a></li>
</ul>
Image: Shutterstock

Bird Flu Puts Teen In Critical Condition As Canada Reports First Human Case: What You Need To Know

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$42.6K</td>
<td>3.5K</td>
<td align="right">672</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$62.50</td>
<td>$50.2K</td>
<td>2</td>
<td align="right">446</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$30.00</td>
<td>$28.1K</td>
<td>7.0K</td>
<td align="right">252</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$51.9K</td>
<td>1.1K</td>
<td align="right">72</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$35.00</td>
<td>$34.0K</td>
<td>38</td>
<td align="right">71</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$36.6K</td>
<td>595</td>
<td align="right">61</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$27.0K</td>
<td>49</td>
<td align="right">59</td>
</tr>
<tr>
<td>IONS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.00</td>
<td>$25.0K</td>
<td>331</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$41.7K</td>
<td>1.1K</td>
<td align="right">42</td>
</tr>
<tr>
<td>RGEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$130.00</td>
<td>$33.0K</td>
<td>21</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 430 day(s) on January 16, 2026. Parties traded 49 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $42.6K, with a price of $870.0 per contract. There were 3515 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with bearish sentiment. It expires in 185 day(s) on May 16, 2025. Parties traded 54 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 2 open contracts at this strike prior to today, and today 446 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 402 day(s) on December 19, 2025. Parties traded 225 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $125.0 per contract. There were 7032 open contracts at this strike prior to today, and today 252 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with bullish sentiment. It expires in 66 day(s) on January 17, 2025. Parties traded 30 contract(s) at a $315.00 strike. The total cost received by the writing party (or parties) was $51.9K, with a price of $1730.0 per contract. There were 1132 open contracts at this strike prior to today, and today 72 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be bullish, expiring in 276 day(s) on August 15, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 38 open contracts at this strike prior to today, and today 71 contract(s) were bought and sold. 
• For JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we notice a put option sweep that happens to be bullish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 61 contract(s) at a $50.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $601.0 per contract. There were 595 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 36 contract(s) at a $340.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $750.0 per contract. There were 49 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For IONS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), we notice a call option trade that happens to be bullish, expiring in 794 day(s) on January 15, 2027. This event was a transfer of 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 331 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be neutral, expiring in 66 day(s) on January 17, 2025. This event was a transfer of 39 contract(s) at a $100.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.7K, with a price of $1070.0 per contract. There were 1154 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding RGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on November 15, 2024. Parties traded 20 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $1650.0 per contract. There were 21 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IONS

JANX

RGEN

TGTX

10 Health Care Stocks Whale Activity In Today's Session

Asset Sales

Pfizer Explores Sale Of Hospital Drugs Unit, Hires Goldman Sachs For Advice

ViiV Healthcare's DOLCE Study Shows 2-Drug Regimen Dovato Is Highly Effective In Treatment-Naïve People With Advanced HIV, Matching 3-Drug Therapy Efficacy At 48 Weeks

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%">
On Thursday, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported third-quarter revenue of $1.83 billion, beating the <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">consensus of $1.25 billion</a>.
The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.
BofA Securities notes that Moderna&#8217;s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company&#8217;s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy&#8217;s positions on vaccines.
The analyst has reduced the <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">price target from $110 to $90</a>, adjusting for a higher discount rate (9% instead of 7%) based on updated commercial risk expectations, lower sales forecasts for COVID-19 and RSV vaccines, and reduced net cash. The analyst maintained a Neutral rating on Moderna.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology">Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology</a>
Leerink Partners notes the earnings update didn&#8217;t improve the negative outlook for COVID and RSV, and the revenue beat, driven by excess inventory, pointed to weak earnings quality.
The company faces challenges from declining COVID demand and losing market share to Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), which could affect Moderna's ability to clear excess inventory and raise concerns about potential write-downs in the fourth quarter of 2024.
Leerink has lowered the price target from $46 to $38, with an Underperform rating.
Oppenheimer remains optimistic about the long-term potential of Moderna's RSV vaccine, mRESVIA growth. &#8220;We think MRNA is well-positioned to extend the mRESVIA label into high-risk adults 18-59, filing an sBLA with PRV by YE24,&#8221; the analyst writes, and maintains the Perform rating.
The analyst notes mRESVIA launch will take longer than expected but still considers it an undervalued asset, particularly with its upcoming label extension.
The analyst also adds, &#8220;We are impressed by MRNA&#8217;s progress toward opex optimization and believe such efficiency could invite a larger upside for its upcoming pipeline launches.&#8221;
The company expects the cost of sales to be 40-45% of product sales for the year (previously 40-50%), with R&amp;D expenses anticipated to be $4.6 billion—<a href="https://www.benzinga.com/calendars/guidance">$4.7 billion (previously $4.8 billion).</a>
Price Action: MRNA stock is down 6.33% at $47.10 at last check Friday.
Photo by Lutsenko_Oleksandr on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report">Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</a></li>
</ul>
</div>
</div>

Analyst Color

Price Target

Reiteration

Analyst Ratings

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

President-elect Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. Trading in pharmaceutical stocks is shaky this week and the details are few surrounding a <a href="https://www.benzinga.com/general/politics">possible appointment</a>.
What To Know: Trump <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">recently said</a> he would let Kennedy &#8220;go wild on health&#8221; and could "do pretty much what he wants" in his administration, but the details remain murky.&nbsp;
Kennedy has a record of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies, <a href="https://www.nytimes.com/2024/11/06/us/politics/robert-kennedy-jr-donald-trump-health-care.html">according</a> to The New York Times. Thirteen measles outbreaks have occurred in the U.S. so far in 2024 versus four last year, and the trend coincides with lower measles vaccination rates, The Times report said, citing the CDC. Kennedy is outspoken about certain food ingredients and the state of key public health agencies including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Kennedy said in <a href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">an interview </a>Wednesday with NBC News that Trump has not yet decided what his job in the new administration will be, but he did mention the prospect of being a &#8220;White House health czar.&#8221;
Kennedy said he wouldn&#8217;t "take away anybody&#8217;s vaccines," but the uncertainty surrounding his potential impact on the country's health care regulators caused vaccine-related stocks to drop. Investors may be trying to get ahead of any negative consequences related to a potential Kennedy appointment.  
&#8220;We view the Trump win as mixed for large-cap biopharma since it creates potential uncertainty regarding Food and Drug Administration independence,&#8221; said Leerink Partners analyst David Risinger, according to Investor's Business Daily.  
Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) ending the day down 2.78%, Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 3.9%, BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) down 3.9% and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) closing down by 3.03%. 
Moderna reported its <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">third-quarter results</a> Thursday morning with $1.8 billion in Spikevax sales and was trading down in the late afternoon. Shares of the other vaccine makers are recovering Thursday, but the uncertainty <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">may continue</a> as details emerge on a Kennedy role in the forthcoming Trump administration. 
"Shoot first reaction being felt across the vaccine complex," wrote Mizuho analyst Jared Holz, as <a href="https://www.wsj.com/livecoverage/stock-market-today-fed-meeting-dow-nasdaq-sp500-live-11-06-2024/card/vaccine-stocks-drop-on-worries-about-an-rfk-jr-role-dBPxZf8JJnNqL1Zi5yZY">reported </a>by the Wall Street Journal. He added that "for now, state mandates for many treatments remain intact."
MRNA, PFE, BNTX, GSK Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Moderna shares are up 2.67% at $50.42, Pfizer shares are up 0.35% at $27.44, BioNTech shares are up 1.29% at $108.02 and GSK shares are up 1.77% at $36.54 ahead of the close Thursday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Image: Shutterstock

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'

<ul>
<li>New analyses highlight use of long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine LA) in clinical trial and real-world populations, and the economic and public health impact of Apretude (cabotegravir LA for PrEP)</li>
<li>Findings from the DOLCE study explore the efficacy of 2-drug regimen Dovato (dolutegravir/lamivudine) compared to three-drug regimen in people with advanced HIV with CD4 count ≤ 200 cells/mm³</li>
<li>Additional key abstracts include findings from pipeline bNAb asset, VH3810109, as a potential approach to treating HIV</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024. Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic.

GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow

Robert Kennedy Jr. has disclosed President-Elect Donald Trump&#8217;s three-fold directive to him, aimed at transforming the nation&#8217;s health landscape.
What Happened: On Wednesday, Kennedy Jr. took to X to share the tasks Trump has assigned to him. He wrote that Trump asked him to do three things: clean up corruption in health agencies, restore evidence-based science, and end the chronic disease epidemic to make America healthy again.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Trump has asked me to do three things: 1. Clean up the corruption in our government health agencies. 2. Return those agencies to their rich tradition of gold-standard, evidence-based science. 3. Make America Healthy Again by ending the chronic disease epidemic. <a href="https://t.co/WHMOsD0CiI">pic.twitter.com/WHMOsD0CiI</a>
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1854281809464529384?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41741814/walgreens-agrees-to-100-million-settlement-over-alleged-deceptive-pricing-of-generic-drugs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs</a>
This announcement comes after Trump&#8217;s previous pledge to give Kennedy <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">full authority over health</a>, food, and medicine issues if he secures a second term. The former President had expressed his intent to allow Kennedy to &#8220;run wild&#8221; on these matters, with the exception of oil.
Kennedy Jr. is known for his contentious views on vaccines and has also been know to speak out regularly on food additives. In the aftermath of the election, shares of pharmaceutical companies, particularly those associated with the COVID-19 vaccine, have slid.
On Wednesday Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Modern Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stocks hovered near their 52-week lows of $25.20 and $49.60 respectively. For the day, PFE ended 2.2% lower at $27.36, while MRNA dropped 2.8% to $51.81. The iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) fell 0.5% to $68.39 in a similar period.
Why It Matters: Kennedy&#8217;s new role and the tasks assigned to him align with Trump&#8217;s earlier statements. In a recent interview, Trump showed tentative support for Kennedy&#8217;s plan to <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">remove fluoride from water</a>, a move aimed at improving public health. Kennedy, known for his health-related advocacies, stated that his administration would encourage all U.S. water systems to eliminate fluoride on its first day in office.
Furthermore, Kennedy had previously disclosed that he might be appointed by Trump to select leaders for <a href="https://www.benzinga.com/news/24/09/40931166/robert-kennedy-jr-trump-wants-him-to-help-pick-cdc-fda-and-nih-leaders-unravel-the-capture-of-agenci">key public health agencies</a>, including the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. This latest announcement seems to confirm his involvement in these agencies, marking a significant shift in the country&#8217;s health policies.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.

Robert F. Kennedy Jr., who will meet with senior Trump aides on Wednesday to discuss his role going forward, said he would eliminate the nutrition departments at the FDA.
<a href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955" title="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955</a>

'After Trump win, RFK Jr. says he won't 'take away anybody's vaccines'' - NBC News

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Pfizer's Recent Short Interest

Contracts

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

On Thursday, ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41669391/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined-with-enzalutami" rel="noreferrer noopener">second-generation antiandrogens</a>.
This decision was based on a protocol-specified interim review of the safety, PK, and efficacy data, which showed a much higher rate of PSA90 response in patients treated with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide) monotherapy (which is the standard of care for this patient population) than expected based on historical data.
In addition, there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.
A futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study.
The combination of masofaniten plus enzalutamide was well-tolerated with no new safety signals and a safety profile similar to that seen in Phase 1 studies.
&#8220;We made the difficult decision to terminate this Phase 2 study following the interim analysis because we concluded that the emerging efficacy profile of masofaniten combined with enzalutamide would not likely meet the primary endpoint of the study, nor our internal requirements for a prostate cancer therapy candidate,&#8221; said&nbsp;David Parkinson, President, and CEO.
As part of the effort to focus its resources, ESSA is also planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40862721/essa-pharma-presents-updated-phase-12-masofaniten-epi-7386-clinical-data-at-the-2024-esmo-congress" rel="noreferrer noopener">with other agents</a>.
As of&nbsp;September 30, 2024, the company had available cash reserves and short-term investments of&nbsp;$126.8 million&nbsp;and net working capital of&nbsp;$124.3 million.
In September, ESSA Pharma announced the presentation of updated dose escalation data from its Phase 1/2 study of masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress.
Across all dose cohorts, 88% of patients (14 of 16) achieved PSA50, 88% of patients (14 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 63% of patients (10 of 16) achieved PSA &lt;0.2ng/mL.
Price Action: EPIX stock was down 69.80% at $1.57 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Run: ai Acquisition Draws European Regulatory Scrutiny On Competition Concerns</a></li>
</ul>

EPIX

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth

President-elect Donald Trump said via Truth Social: "I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and H...

Trump names Robert Kennedy as Secretary of Health and Human Services

Wolfe Research initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target Published first on TheFly – the ultimate source ...

Pfizer initiated with an Underperform at Wolfe Research

Vaccine makers close lower amid reports RFK Jr may head HHS

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading... Defensive stocks are stocks of companies that deliver products and services of essential or <a href="https://www.investopedia.com/terms/d/defensivestock.asp">necessary nature like healthcare, medicines</a>, basic utilities, consumer goods, etc. The demand for such companies is the same through various business cycles, and therefore, they offer stable income and growth prospects to investors, making them ideal investment choices during market uncertainties.
Given this backdrop, it could be wise to invest in quality defensive stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>) for stability amid market volatility.
The U.S. economy has been showing mixed growth this year with each quarter. The economy grew at a 1.3% annualized rate in the first quarter, indicating slow expansion, whereas during the second quarter, the rate rose to 3.0%, fueled by strong household income growth and consumer spending.
Last week, the Bureau of Economic Analysis (BEA) <a href="https://www.commerce.gov/news/blog/2024/11/commerce-data-show-strong-economic-gains-due-americans-making-and-spending-more#:~:text=The%20U.S.%20Commerce%20Department's%20Bureau,Americans%20making%20and%20spending%20more.">reported GDP growth of 2.8%</a> at an annual rate in the third quarter of 2024, lower than the economists' estimate of 3.0%. The development during the quarter was driven by increasing consumer spending, which increased by 3.7%, the highest since the first quarter of 2023.
This market volatility has caused investors to seek defensive stocks that remain stable during market downturns and offer stable income through dividends and long-term growth opportunities.
Demand for healthcare amenities remains constant, as the need for medical treatments remains the same regardless of economic conditions. Hence, the sector offers investors stability and protection during market downturns. Likewise, basic utilities such as goods and services like water, gas, and electricity cannot be avoided or subset, given their necessity for survival.
Therefore, investing in defensive stocks amidst economic uncertainties is ideal due to constant consumer demand, stable income, and portfolio protection. Given these factors, let's delve deeper into the fundamentals of the top defensive stocks: JNJ, PFE, and GNE.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells various products in the healthcare field internationally. The company operates in the Innovative Medicine and MedTech segments. It offers products for various therapeutic areas, like immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.
On October 28, JNJ announced results from the Phase 3 GRAVITI study of TREMFYA&#xAE; (guselkumab), the first and only IL-23 inhibitor. TREMFYA showed robust subcutaneous induction and maintenance therapy results, demonstrating significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.
Upon FDA approval, TREMFYA&#xAE; could become the first IL-23 treatment to offer a subcutaneous and intravenous (IV) induction regimen for patients with Crohn's disease (CD).
On October 9, JNJ completed the acquisition of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisitions added V-Wave's novel and minimally invasive Ventura&#xAE; interatrial shunt to the Johnson &amp; Johnson MedTech portfolio and will also strengthen its position in the cardiovascular disease segment.
During the nine months that ended September 30, 2024, JNJ's reported sales increased 4% year-over-year to $66.30 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 4.4% year-over-year to $45.96 billion. The company's net earnings from continuing operations of $10.64 billion and $4.83 indicate increases of 15.7% and 24.1% from the prior year's period, respectively.
Analysts expect JNJ's EPS for the fourth quarter (ending December 2024) to increase 0.9% year-over-year to $2.31, and its revenue is estimated to increase 5% year-over-year to $22.47 billion for the same quarter. Moreover, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
JNJ's stock has soared 9.7% over the past month and 2.5% over the past six months to close the last trading session at $160.62.
JNJ's growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Stability, Quality, and Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #14 out of 160 stocks.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to access additional ratings of JNJ for Growth, Sentiment, and Momentum.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers medicines and vaccines in various therapeutic areas like cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands.
On October 22, PFE received the U.S. FDA approval for its ABRYSVO&#xAE; (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals between 18 and 59 years of age. ABRYSVO offers the broadest indication of the RSV vaccine in adults.
The approval was based on data from the pivotal Phase 3 trial. ABRYSVO is the first and only respiratory syncytial virus vaccine indicated for adults younger than 50. Also, the indication has now been expanded to benefit older adults and pregnant women.
Also, in the same month, PFE received FDA approval for HYMPAVZI&#x2122; (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A. The approval marked a significant advancement for people living with hemophilia A or B without inhibitors for bleed prevention.
During the third quarter that ended September 29, 2024, PFE's total revenues rose 31.2% from the prior-year quarter to $17.70 billion, of which its product revenues grew 33.1% year-over-year to $15.42 billion. The company's adjusted net income and EPS came in at $6.05 billion and $1.06 for the quarter, respectively.
The company had raised its full-year 2024 revenue guidance to a range of $61 billion to $64 billion from the prior range of $59.50 to $62.50 billion. PFE also raised its adjusted EPS guidance to a range of $2.75 to $2.95.
The consensus EPS estimate of $0.46 for the fiscal fourth quarter (ending December 2024) represents a 358% improvement year-over-year. The consensus revenue estimate of $17.36 billion for the ongoing quarter represents a 21.9% increase from last year. The company has an impressive surprise history; it surpassed the consensus EPS estimates in all of the trailing four quarters.
PFE's stock has surged 0.7% over the past six months and 3.9% over the past nine months to close the last trading session at $27.99.
PFE's bright outlook is reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Value. PFE is ranked #37 among the 160 stocks in the Medical - Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's other ratings for Quality, Momentum, Stability, and Sentiment.
Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>)
GNE is engaged in the supply of electricity and natural gas to residential and small business customers internationally. The company operates in two segments, GRE and Genie Renewables. It develops, constructs, and operates solar energy projects for commercial and industrial customers.
On March 21, GNE's subsidiary, Sunlight Energy Investments, a retail energy and renewable energy solutions provider, purchased a late-stage solar development project in Hamilton, Indiana, from the project developer. The Hamilton project acquisition fits perfectly with the company's growing portfolio of solar projects, which offers long-term, stable cash flows.
GNE reported total revenue of $90.70 million for the second quarter that ended June 30, 2024, and its income from operations was $10.56 million for the same period. The company's net income attributable to Genie common stockholders and EPS came in at $9.61 million and $0.36 for the quarter, respectively.
Shares of GNE have declined marginally over the past six months to close the last trading session at $15.67.
GNE's POWR Ratings reflect its robust outlook. GNE has an overall B rating, equating to a Buy in our proprietary rating system.
The stock has a B grade for Quality, Sentiment, Momentum, and Value. It is ranked #2 among the 59 stocks in the <a href="https://stocknews.com/category/utilities-domestic/">Utilities - Domestic</a> industry.
<a href="https://stocknews.com/stock/GNE/">Click here</a> to access additional GNE ratings for Stability and Growth.Top of Form
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $158.20 per share on Wednesday afternoon, down $0.15 (-0.09%). Year-to-date, JNJ has gained 3.30%, versus a 25.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-gne-3-defensive-stocks-to-buy-as-market-volatility-rises/>3 Defensive Stocks to Buy as Market Volatility Rises</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Defensive Stocks to Buy as Market Volatility Rises

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more… With a growing population and rising rates of chronic conditions, the demand for better healthcare solutions has never been greater. Thus, scooping shares of fundamentally sound healthcare stocks, Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>), could provide significant gains and long-term stability.
Chronic diseases are becoming more prevalent worldwide, leading to a surge in demand for innovative treatments. As conditions like heart disease, diabetes, and respiratory issues rise, healthcare providers and pharmaceutical companies must meet the increasing need for effective and accessible solutions to manage these ailments.
That said, Artificial intelligence (AI) and machine learning are <a href="https://health.clevelandclinic.org/ai-in-healthcare">reshaping the healthcare landscape</a>. By improving task management, patient services, and complex measurements, AI is streamlining operations and accelerating the healthcare industry's growth, making it more efficient and patient centric.
Moreover, the industry continues to demonstrate its potential, as seen with the U.S. Food and Drug Administration's <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approval of 38 new drugs</a> for chronic conditions this year. With global pharmaceutical revenue expected to <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">hit $1.45 trillion by 2029</a>, growing at a steady CAGR of 4.7%, the future of healthcare looks promising.
With these conductive trends in mind, let us dive deep into the fundamentals of three healthcare stocks, starting with #3.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells a variety of healthcare products. Its offerings address conditions such as immunology, infectious diseases, neuroscience, oncology, and pulmonary hypertension. The company operates through two segments: Innovative Medicine and MedTech.
On October 10, JNJ <a href="https://s203.q4cdn.com/636242992/files/doc_news/2024/Oct/10/final-volt-press-release-us_dps_trex_391290.pdf">announced the launch</a> of the first phase of VOLT&#x2122; Variable AngleOptimized Locking Technology Plating System, an innovative system for fracture management solutions. This positions JNJ to strengthen its presence in the orthopedic trauma market, driving market share growth and stable opportunities.
On October 9, JNJ <a href="https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-Completes-Acquisition-of-V-Wave/default.aspx">announced the completion of acquisition</a> of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisition could allow JNJ to broaden its product offerings and capitalize on emerging opportunities in the growing field of heart disease management.
For the fiscal 2024 third quarter that ended on September 29, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> also grew 5.2% from the year-ago value to $15.51 billion. Additionally, the company's net earnings and net earnings per share from continuing operations came in at $2.69 billion and $1.11, respectively.
Analysts expect JNJ's revenue for the fiscal year ending December 2024 to increase 4.3% year-over-year to $88.79 billion. Its EPS for the ongoing fiscal year is expected to grow marginally from the previous year to $9.96. Plus, the company topped the consensus EPS estimates in all four trailing quarters.
JNJ's stock has increased by 6.1% over the past six months, closing the last trading session at $158.35. The company maintains a 24-month beta of 0.25, reflecting its relatively low market volatility.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its strong fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
JNJ has a B grade for Value, Stability, and Quality. It is ranked #14 out of 160 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry.
To check the stock's ratings for Growth, Sentiment, and Momentum, <a href="https://stocknews.com/stock/JNJ/">click here</a>.
Stock #2: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global, research-driven biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products. It provides medicines and vaccines in therapeutic areas such as cardiovascular metabolic, migraine, and women's health.
On October 22, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-RSV-Vaccine-ABRYSVO-for-Adults-Aged-18-to-59-at-Increased-Risk-for-Disease/default.aspx">announced the U.S. Food and Drug Administration (FDA) approval</a> of ABRYSVO, bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
With this approval, the company could expand its footprint in infectious disease prevention, opening doors to new opportunities and solidifying its reputation as a leader in innovative healthcare solutions.
On October 11, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-HYMPAVZI-marstacimab-hncq-for-the-Treatment-of-Adults-and-Adolescents-with-Hemophilia-A-or-B-Without-Inhibitors/default.aspx">announced the FDA approval</a> for HYMPAVZI, a drug for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
The approval strengthens PFE's position in the rare disease market. As the company broadens its therapeutic offerings, HYMPAVZI provides a vital tool for managing hemophilia, paving the way for increased growth in this specialized area of healthcare.
For the fiscal third quarter that ended on September 29, 2024, PFE's total revenues increased 31.2% year-over-year to $17.70 billion. The adjusted net income and adjusted earnings per common share attributable to PFE common shareholders stood at $6.05 billion and $1.06, compared to a net loss and loss per share of $968 million and $0.17 in the prior year's quarter, respectively.
Street expects PFE's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 21.9% and 358% year-over-year to $17.36 billion and $0.46, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters.
PFE's stock has risen 5.3% over the last nine months, with the latest close at $27.99. The company's 24-month beta stands at 0.23, highlighting its lessened exposure to market fluctuations.
PFE's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PFE has an A grade for Growth and a B for Value. It is ranked #37 within the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's ratings for Quality, Momentum, Stability, and Sentiment.
Stock #1: The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>)
CI offers insurance and related services. Its Evernorth segment provides coordinated and point-solution health services. Meanwhile, the Cigna Healthcare segment delivers medical, pharmacy, behavioral health, dental, and other products, including Medicare plans and international health coverage for individuals and employees.
On January 31, CI <a href="https://newsroom.thecignagroup.com/2024-01-31-The-Cigna-Group-to-Sell-Medicare-Businesses-and-CareAllies-to-Health-Care-Service-Corporation-HCSC">announced a definitive agreement</a> for Health Care Service Corporation (HCSC) to acquire its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses for an approximate transaction value of $3.7 billion. This would enable CI to unlock substantial value for stakeholders by freeing up resources to accelerate investment in its services platform.
For the fiscal third quarter that ended on September 30, 2024, CI's adjusted revenues increased 29.8% year-over-year to $63.70 billion. Its adjusted income from operations rose 5% from the year-ago value to $2.11 billion. Moreover, the company's adjusted income from operations per share rose 10.9% from the prior year's quarter to $7.51.
The consensus revenue estimate of $62.91 billion for the fiscal fourth quarter (ending December 2024) reflects a year-over-year rise of 23%. Its EPS for the same period is expected to increase 15.4% from the prior year's period to $7.84. Also, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
CI's shares have gained 6.3% year-to-date, closing the last trading session at $318.39. The stock holds a 24-month beta of 0.13, indicating its low volatility in comparison to broader market movements.
CI's POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CI has a B grade for Growth, Value, and Sentiment. It has topped the 10-stock A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
To check CI's Quality, Momentum, and Stability ratings, <a href="https://stocknews.com/stock/CI/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
JNJ shares were unchanged in premarket trading Wednesday. Year-to-date, JNJ has gained 3.40%, versus a 22.48% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-ci-3-healthcare-stocks-for-long-term-stability-and-growth/>3 Healthcare Stocks for Long-Term Stability and Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks for Long-Term Stability and Growth

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, investors could consider fundamentally sound, high dividend yield stocks Verizon Communications (VZ), Pfizer (PFE), and Enterprise Products Partners (EPD) for steady passive income. Read more... High-dividend yield stocks allure investors with attractive yield levels, regular income streams, and growth potential in the long run. These stocks also have the potential to optimize investment portfolios against economic volatility and offer wide long-term growth prospects.
Against this backdrop, it could be wise to invest in fundamentally strong high dividend yield stocks Verizon Communications Inc. (<a href="https://stocknews.com/stock/VZ/">VZ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and Enterprise Products Partners L.P. (<a href="https://stocknews.com/stock/EPD/">EPD</a>) could be ideal buys for steady passive income.
The U.S. economy shows mixed signals, urging investors to seek stable investment alternatives. Amid this, high dividend yield stocks stand out as they offer a combination of reliable income and gradual capital appreciation, suitable for investors seeking passive income and protection from economic volatility.
During the third quarter, the <a href="https://www.bea.gov/news/2024/gross-domestic-product-third-quarter-2024-advance-estimate">U.S. economy's real gross domestic product</a> increased at an annual rate of 2.8%, according to the "advance" estimate of the U.S. Bureau of Economic Analysis. The growth in the current quarter was propelled by solid consumer spending and favorable government spending. The growth was lower than the second quarter real GDP of 3.0%.
The GDP growth was also below the 3.1% estimate of economists. Further, continuous import growth, outpacing export growth, contributes to the economic slowdown. <a href="https://www.conference-board.org/brief/global-economy/gdp-q3-2024#:~:text=Real%20GDP%20growth%20remained%20healthy,anticipated%20roughly%203%20percent%20growth.">For the fourth quarter</a>, the real GDP growth is also expected to be slow as hurricane effects and inventory destocking limited the expansion. Also, speculation of another rate cut and inflation continue to be a concern.
Therefore, against the economic uncertainties, high-dividend yield stocks pose a bright investment prospect for investors. The benefit of dividends makes a stock more appealing to investors, providing potential for regular dividend earnings and capital appreciation. Also, investing in high dividend-yield stocks ensures that the company is performing well financially.
Given the economic trends, investing in high dividend yield stocks with dividend yield above 5%, such as VZ, PFE, and EPD, could be wise for future gains.
Verizon Communications Inc. (<a href="https://stocknews.com/stock/VZ/">VZ</a>)
VZ offers international communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities. The company operates through Verizon Consumer Group (Consumer) and Verizon Business Group (Business) segments.
On October 24, VZ launched its new app, Verizon Family, a digital service that helps families stay connected and safe. The app helps in monitoring a family's location, is built with new features like Safe Walk with an SOS button to contact a family member in an emergency, and even keeps an eye on children's Verizon calls and texts.
The new Verizon family app enhances family safety and is currently available for free to VZ customers on any postpaid plan via the App Store and Google Play.
On October 23, Verizon Frontline launched two new deployable asset prototypes designed to support the mission-critical communications needs of first responders during public safety operations. The two new Verizon Frontline prototype assets are capable of establishing their own off-grid network, allowing first responders to communicate with each other in challenging situations.
Also, on September 4, VZ increased its quarterly <a href="https://www.investopedia.com/terms/d/dividend.asp">dividend</a> by 1.25 cents to $0.6775 per share, paid to its shareholders on November 1, 2024.
VZ has raised its annual dividend for 20 consecutive years. It pays an annual dividend of $2.71, which translates to a yield of 6.55% at the current share price. Its four-year average dividend yield is 5.87%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 1.9% over the past three years.
For the third quarter that ended September 30, 2024, VZ reported total operating revenues of $33.33 billion, and its operating income came in at $5.93 billion for the same period. The company's net income and EPS totaled $3.41 billion and $0.78 for the quarter.
Furthermore, the company's cash and cash equivalents stood at $4.99 billion as of September 30, 2024, compared to $2.06 billion as of December 31, 2023.
Analysts expect VZ's revenue and EPS for the fourth quarter (ending December 2024) to grow 0.9% and 2.9% year-over-year to $35.45 billion and $1.11, respectively. Also, the company topped the consensus EPS estimates in three of the four trailing quarters.
Shares of VZ have surged 5.5% over the past six months and 16.8% over the past year to close the last trading session at $41.36.
VZ's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
VZ has a B grade for Growth and Stability. It is ranked #4 out of 20 stocks in the C-rated <a href="https://stocknews.com/category/telecom-domestic/">Telecom - Domestic</a> industry.
In addition to the POWR Ratings we've stated above, we also have VZ ratings for Quality, Momentum, Value, and Sentiment. Get all VZ ratings <a href="https://stocknews.com/stock/VZ/">here</a>.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products internationally. The company provides medicines and vaccines in various therapeutic areas, like cardiovascular metabolic, migraine, and women's health, under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands.
On October 22, PFE announced that the U.S. FDA approved its ABRYSVO&#xAE; (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals between 18 and 59 years of age.
The approval is based on data from the pivotal Phase 3 trial. ABRYSVO offers the broadest indication of the RSV vaccine in adults. It is the first and only respiratory syncytial virus vaccine for adults younger than 50. The indication has been expanded to benefit older adults and pregnant women.
On October 11, PFE received FDA approval for HYMPAVZI&#x2122; (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A.
The approval of HYMPAVZI marked a significant advancement for people living with hemophilia A or B without inhibitors for bleed prevention.
On October 9, PFR's Board of Directors declared a $0.42 fourth-quarter 2024 dividend on its common stock, payable on December 2, 2024, to holders of record at the close of business on November 8, 2024.
PFE pays an annual dividend of $1.68, which translates to a yield of 5.98% at the current share price. Its four-year average dividend yield is 4.24%. Moreover, the company's dividend payouts have increased at a CAGR of 4.4% over the past five years. PFE has raised its dividend for 13 consecutive years.
In the third quarter that ended September 29, 2024, PFE's total revenues increased 31.2% year-over-year to $17.70 billion, of which its product revenues grew 33.1% from the year-ago value to $15.42 billion. The company's adjusted net income and adjusted EPS came in at $6.05 billion and $1.06 for the quarter, respectively.
Buoyed by strong financial performance, the company raised its full-year 2024 revenue guidance to a range of $61 billion to $64 billion from the prior range of $59.50 to $62.50 billion. It also raised its adjusted EPS guidance to a $2.75 to $2.95 range.
Street expects PFE's revenue and EPS for the fourth quarter (ending December 2024) to increase 22.1% and 362.8% year-over-year to $17.40 billion and $0.46, respectively. Furthermore, the company topped the consensus EPS estimates in all four trailing quarters.
PFE's stock has surged 3.4% over the past six months to close the last trading session at $28.09.
PFE's bright prospects are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Growth. PFE also has a B grade for Value. PFE is ranked #32 among 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's ratings for Quality, Momentum, Stability, and Sentiment.
Enterprise Products Partners L.P. (<a href="https://stocknews.com/stock/EPD/">EPD</a>)
EPD offers midstream energy services to producers and consumers of natural gas, natural gas liquids, crude oil, petrochemicals, and refined products. The company operates through four segments: NGL Pipelines &amp; Services; Crude Oil Pipelines &amp; Services; Natural Gas Pipelines &amp; Services; and Petrochemical &amp; Refined Products Services.
On October 29, EPD completed the second phase of its Texas Western Products system. Located in Grand County, Utah, the facility is a refined products truck terminal serving the Grand Junction, Colorado, and Moab, Utah areas. The facility has a storage capacity of 400,000 barrels for gasoline and diesel and can load trucks at a rate of up to 20,000 bpd.
On October 28, EPD completed the acquisition of Piñon Midstream, LLC. EPD purchased Piñon Midstream for $950 million in cash consideration as part of a debt-free transaction. The assets acquired under the transaction, including natural gas gathering and treating services, expanded EPD's footprint in the eastern flank of the prolific Delaware Basin of Texas and New Mexico.
Also, on October 2, EPD's Board of Directors declared a quarterly cash distribution to be paid to common unitholders for the third quarter of 2024 of $0.525 per unit. The distribution represents a 5% increase over the distribution declared last year. The distribution will be paid on November 14, 2024, to common unitholders of record as of the close of business on October 31, 2024.
EPD's annual distribution of $2.10 translates to a yield of 7.29% at the current unit price. Its four-year average dividend yield is 7.53%. Also, the company's dividend payouts have increased at a CAGR of 4.9% over the past three years. EPD has raised its dividend for 26 consecutive years.
During the third quarter of 2024, which ended September 30, 2024, EPD's total revenues increased 14.8% from the prior year period to $13.78 billion. Its operating income grew 5% from the year-ago value to $1.78 billion. The company's net income attributable to common unitholders amounted to $1.42 billion or $0.65 per unit, up 7.5% and 8.3% year-over-year, respectively.
In addition, the company's adjusted EBITDA rose 4.9% from the year-ago value to $2.44 billion.
Street expects EPD's EPS for the first quarter (ending March 2025) to increase 4.5% year-over-year to $0.70, and its revenue for the same quarter is expected to grow marginally year-over-year to $14.85 billion. Also, the company has surpassed the consensus EPS estimates in three of the trailing four quarters.
EPD's stock has gained 3.9% over the past six months and 11% over the past year to close the last trading session at $28.82.
EPD's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value, Momentum, and Stability. Within the A-rated <a href="https://stocknews.com/category/oil-gas-mlps/">MLPs – Oil &amp; Gas</a> industry, EPD is ranked #5 among 23 stocks.
<a href="https://stocknews.com/stock/EPD/">Click here</a> to access additional EPD ratings for Sentiment, Growth, and Quality.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;

<hr />
VZ shares were unchanged in after-hours trading Monday. Year-to-date, VZ has gained 16.17%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/vz-pfe-epd-3-high-yield-dividend-stocks-to-buy-for-steady-passive-income/>3 High-Yield Dividend Stocks to Buy for Steady Passive Income</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Yield Dividend Stocks to Buy for Steady Passive Income

Vaccine makers close lower amid reports RFK Jr may head HHS (update)

Wolfe Research initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target While it can be challenging to move the needle o...

Wolfe starts Pfizer at Underperform, notes underperformance versus peers

AAPL

ALNY

ARCC

BBIO

GOOG

GOOGL

MAIN

MSFT

SCHD

SCHO

TCPC

VICI

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Tim Buckley Elected to Pfizer's Board of Directors

ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024

Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow

ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV

KVUE

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Pfizer

Noticias

Últimas noticias sobre Pfizer (NYSE:PFE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL